CALCIUM LEVOFOLINATE clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after first-lIne chemotherapy and target agents: The HAITI study.
This study looks at a new way to treat bowel cancer that has spread only to the liver and can't be removed with surgery. It combines a special radiation treatment with regular cancer medicines to see if it can stop the cancer from growing for longer. It's for adults who have already had some chemotherapy.
For: Liver limited unresectable colorectal cancerItaly - Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
This study looks at new drug combinations for advanced stomach or food pipe cancer. It compares a new mix of drugs (Lenvatinib, Pembrolizumab, and chemotherapy) against the usual treatment to see which works best and is safest for patients.
For: Advanced/Metastatic Gastroesophageal AdenocarcinomaSpain · Belgium · Germany - Ongoing, recruitingPhase II and Phase III (Integrated)
PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma
This study is looking at a new way to treat advanced stomach and gullet cancer. It compares a standard chemotherapy treatment with the same treatment plus an extra drug to see if it helps people live longer without their cancer growing. It involves adults with this type of cancer.
For: Locally advanced or metastatic oesogastric adenocarcinomaFrance - AuthorisedTherapeutic confirmatory (Phase III)
NACRE 2_Randomized phase III study evaluating two treatment strategies for locally advanced rectal cancer in patients ≥75 years old
This study is looking at different ways to treat advanced bowel cancer in people over 75, comparing standard surgery with a plan that tries to avoid major surgery while still aiming for a good outcome. It wants to see which approach works best.
For: Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy · FOLFOX chemotherapy and total mesorectal excision (TME) surgeryFrance